Seres Therapeutics Inc (MCRB)

May 06, 2025

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - The Globe and Mail

May 06, 2025

May 06, 2025

Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $80.00 - Defense World

May 06, 2025

May 05, 2025

Seres Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView

May 05, 2025

May 01, 2025

Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com - Defense World

May 01, 2025

Apr 29, 2025

Seres Therapeutics Reveals Game-Changing Biomarkers for IBD Treatment, Seeks Development Partners - Stock Titan

Apr 29, 2025

Apr 29, 2025

Seres Therapeutics (MCRB) to Unveil New Findings at 2025 Digesti - GuruFocus

Apr 29, 2025

Apr 29, 2025

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - The Manila Times

Apr 29, 2025

Apr 28, 2025

Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Weak at 0.70, Down -2.90 - DWinneX

Apr 28, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 25, 2025

Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - Defense World

Apr 25, 2025

Apr 24, 2025

MCRB Stock Update: Seres Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com

Apr 24, 2025

Apr 24, 2025

Seres Therapeutics Inc (MCRB) expanding its growth trajectory ahead - Sete News

Apr 24, 2025

Apr 23, 2025

Seres Therapeutics Reveals Q1 2025 Results: Live Biotherapeutics Pioneer Updates Growth Strategy - Stock Titan

Apr 23, 2025

Apr 23, 2025

Seres Therapeutics enacts 1-for-20 reverse stock split By Investing.com - Investing.com India

Apr 23, 2025

Apr 22, 2025

Seres Therapeutics enacts 1-for-20 reverse stock split - Investing.com

Apr 22, 2025

Apr 22, 2025

JP Morgan downgrades Seres Therapeutics Inc (MCRB) rating to an Underweight - knoxdaily.com

Apr 22, 2025

Apr 21, 2025

Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating - marketscreener.com

Apr 21, 2025

Apr 21, 2025

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 - marketscreener.com

Apr 21, 2025

Apr 21, 2025

Upcoming Stock Splits This Week (April 21 to April 25) – Stay Invested - The Globe and Mail

Apr 21, 2025

Apr 17, 2025

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround - NewsBreak: Local News & Alerts

Apr 17, 2025

Apr 16, 2025

MCRB stock touches 52-week low at $0.46 amid market challenges By Investing.com - Investing.com South Africa

Apr 16, 2025

Apr 16, 2025

MCRB stock touches 52-week low at $0.46 amid market challenges - Investing.com

Apr 16, 2025

Apr 14, 2025

Seres Therapeutics enacts stock incentive plan and reverse split By Investing.com - Investing.com South Africa

Apr 14, 2025

Apr 14, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Apr 14, 2025

Apr 14, 2025

Seres Therapeutics enacts stock incentive plan and reverse split - Investing.com

Apr 14, 2025

Apr 14, 2025

Seres Therapeutics Approves Reverse Stock Split Plan - TipRanks

Apr 14, 2025

Apr 12, 2025

Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at StockNews.com - Defense World

Apr 12, 2025

Apr 11, 2025

Seres Therapeutics Inc (NASDAQ: MCRB): Blank Check On Growth? - stocksregister.com

Apr 11, 2025

Apr 11, 2025

Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target at $4.00 - Defense World

Apr 11, 2025

Apr 09, 2025

Strategic Power Move: Kymera Lands M&A Expert to Accelerate Drug Development Deals - Stock Titan

Apr 09, 2025

Apr 08, 2025

MCRB stock touches 52-week low at $0.54 amid market challenges - Investing.com Australia

Apr 08, 2025

Apr 08, 2025

MCRB stock touches 52-week low at $0.54 amid market challenges By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 03, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of Seres Therapeutics, Inc.MCRB - ACCESS Newswire

Apr 03, 2025

Apr 02, 2025

5 Best Microbiome Companies (May 2025) - Securities.io

Apr 02, 2025

Apr 01, 2025

Charles Schwab Investment Management Inc. Purchases 117,107 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Apr 01, 2025

Mar 28, 2025

FY2025 Earnings Forecast for MCRB Issued By Chardan Capital - Defense World

Mar 28, 2025

Mar 28, 2025

Avantax Advisory Services Inc. Increases Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Mar 28, 2025

Mar 23, 2025

Seres Therapeutics (NASDAQ:MCRB) Given "Buy" Rating at Chardan Capital - MarketBeat

Mar 23, 2025

Mar 22, 2025

Chardan Capital Reiterates Buy Rating for Seres Therapeutics (NASDAQ:MCRB) - Defense World

Mar 22, 2025

Mar 21, 2025

Microbiome Disease Pipeline Insight 2025: Over 180 Drugs in Development Across 140+ Companies - GlobeNewswire Inc.

Mar 21, 2025

Mar 20, 2025

Petri Dish: Flagship spinout Ampersand raises $65M, Seres medical chief lands new role - The Business Journals

Mar 20, 2025

Mar 17, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $4.00 Consensus Target Price from Brokerages - Defense World

Mar 17, 2025

Mar 16, 2025

The Goldman Sachs Group Issues Pessimistic Forecast for Seres Therapeutics (NASDAQ:MCRB) Stock Price - Defense World

Mar 16, 2025